Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$5.70|
|52 Week High||AU$1.61|
|52 Week Low||AU$7.65|
|1 Month Change||-16.18%|
|3 Month Change||8.16%|
|1 Year Change||237.28%|
|3 Year Change||551.43%|
|5 Year Change||n/a|
|Change since IPO||640.26%|
Recent News & Updates
|TLX||AU Biotechs||AU Market|
Return vs Industry: TLX exceeded the Australian Biotechs industry which returned 2.5% over the past year.
Return vs Market: TLX exceeded the Australian Market which returned 21.1% over the past year.
Stable Share Price: TLX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: TLX's weekly volatility (8%) has been stable over the past year.
About the Company
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer).
Telix Pharmaceuticals Fundamentals Summary
|TLX fundamental statistics|
Is TLX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TLX income statement (TTM)|
|Cost of Revenue||AU$1.98m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.21|
|Net Profit Margin||-907.00%|
How did TLX perform over the long term?See historical performance and comparison
Is Telix Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TLX (A$5.7) is trading below our estimate of fair value (A$10.57)
Significantly Below Fair Value: TLX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TLX is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: TLX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TLX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TLX is overvalued based on its PB Ratio (33.9x) compared to the AU Biotechs industry average (4.8x).
How is Telix Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: TLX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TLX's is expected to become profitable in the next 3 years.
Revenue vs Market: TLX's revenue (75.4% per year) is forecast to grow faster than the Australian market (5.4% per year).
High Growth Revenue: TLX's revenue (75.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TLX's Return on Equity is forecast to be low in 3 years time (16.4%).
How has Telix Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TLX is currently unprofitable.
Growing Profit Margin: TLX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TLX is unprofitable, and losses have increased over the past 5 years at a rate of 52.8% per year.
Accelerating Growth: Unable to compare TLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: TLX has a negative Return on Equity (-123.3%), as it is currently unprofitable.
How is Telix Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: TLX's short term assets (A$70.3M) exceed its short term liabilities (A$22.3M).
Long Term Liabilities: TLX's short term assets (A$70.3M) exceed its long term liabilities (A$58.6M).
Debt to Equity History and Analysis
Debt Level: TLX's debt to equity ratio (0.09%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TLX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TLX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TLX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Telix Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TLX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TLX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TLX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Behrenbruch (46 yo)
Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD315.65K) is below average for companies of similar size in the Australian market ($USD1.42M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
Experienced Management: TLX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: TLX's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.3%.
Telix Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Telix Pharmaceuticals Limited
- Ticker: TLX
- Exchange: ASX
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$1.625b
- Shares outstanding: 285.07m
- Website: https://www.telixpharma.com
Number of Employees
- Telix Pharmaceuticals Limited
- 55 Flemington Road
- Suite 401
- North Melbourne
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:21|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.